Fresh, normal human renal cortical tissue homogenate was used as immunogen to generate the RCC antibody.
Cell surface and cytoplasmic
Recognizes a glycoprotein of ~200kDa, identified as carbonic anhydrase IX (CAIX/gp200). Its epitope resides in the carbohydrate domain of gp200. It shows no significant cross-reactivity with other carbohydrate determinants, such as the Lewis blood group antigens, epithelial membrane antigen, HMFG, and AB blood group antigens. In normal kidney, gp200 is localized along the brush border of the pars convoluta and pars recta segments of the proximal tubule, as well as focally along the luminal surface of Bowman's capsule adjoining the outgoing proximal tubule. Reportedly, gp200 is expressed by 93% of primary and 84% of metastatic renal cell carcinomas. This MAb may be useful in the investigations of carcinomas of proximal nephrogenic differentiation especially those showing tubular differentiation.
Protein G purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Alternate Names for Renal Cell Carcinoma (gp200) Antibody (66.4.C2 (PN-15))
C-type lectin domain family 13 member B
lymphocyte antigen 75
Renal cell carcinoma (RCC) is a common form of kidney cancer that poses challenges for the pathologist (reviewed in Ingold et al, 2008). Firstly, renal cell carcinoma (RCC) may initially present as a metastatic lesion of an undetected primary tumor. Secondly, a late occurrence of renal cell carcinoma metastasis after nephrectomy can make it difficult to confirm renal origin. Thirdly, metastatic renal cell carcinoma has morphological similarities with various types of primary non-renal tumors thereby compounding typing challenges. In view of these issues, antibodies recognizing protein markers associated with a given cancer have become important tools for tumor classification. The renal cell carcinoma (RCC) monoclonal antibody marker, also known as RCC-ma, is a marker for renal cell carcinoma (reviewed in Ingold et al, 2008). The 66.4.C2 antibody has been used in antibody panels to help determine or rule out renal cell carcinoma. For example, a kidney mass removed from a neonate with suspected tuberous sclerosis complex was negative for renal cell carcinoma antibody staining and it was determined that renal cell carcinoma was not present (Murkami et al, 2012). In contrast, a kidney mass from a child was positive for renal cell carcinoma antibody staining and the mass was defined as a renal cell carcinoma (Chen et al, 2012). The actual protein recognized by RCC-ma antibody is a 200 kDa glycoprotein (gp200) expressed in renal epithelial cells. In normal tissue, the renal cell carcinoma/RCC-ma/gp200 antibody stains the brush border of proximal renal tubules in human kidneys. Renal cell carcinoma antibody reactivity has been described in up to 93% of primary human renal cell carcinomas and 84% of renal cell carcinoma metastases. The clone 66.4.C2 antibody has also been used to help make a diagnosis of renal cell carcinoma in a horse with a mass of unknown origin (Swain et al, 2005). Gp200 is also expressed in some non-kidney tissues including breast tubules and ducts, the surface of epididymal tubular epithelia, and the colloid of thyroid follicles. However because of the reported high expression of gp200 in renal cell carcinoma, gp200 is most commonly referred to as Renal Cell Carcinoma Marker.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.